Literature DB >> 20178092

Antipsychotic use patterns in persons initially treated with mood stabilizers: a naturalistic study.

H Verdoux1, A Cougnard, G-R Auleley, J Deligne, C Blum-Boisgard, B Bégaud, M Tournier.   

Abstract

INTRODUCTION: Little information is available on the pattern of use of antipsychotics in naturalistic conditions in persons initially treated with "conventional" mood stabilizers (lithium and anticonvulsants).
METHODS: Data on community prescriptions were extracted from the 2004-2006 claims database of a French health care insurance fund for self-employed workers. Patients included were those continuously exposed to mood stabilizers without concomitant dispensing of antipsychotics over at least a 3-month period.
RESULTS: Of the 3 958 persons included, 17.8% had at least one addition/switch to antipsychotics over the follow-up period. The most frequent pattern was addition of second-generation antipsychotics (SGAPs) (41%) or first-generation antipsychotics (FGAPs) (23%) to the mood stabilizer for a relatively short period of time. A switch from mood stabilizer to SGAPs (20%) or FGAPs (15%) was less frequent. Mood stabilizers alone were prescribed again in most patients with the addition of FGAPs (72%) or SGAPs (61%) to mood stabilizers. Conversely, the majority of patients with a switch from mood stabilizers to FGAPs (55%) or SGAPs (58%) went on with these latter treatments over the follow-up.
CONCLUSIONS: SGAPs are preferentially prescribed in combination with mood stabilizers and their pattern of use is similar to that of FGAPs. (c) Georg Thieme Verlag KG Stuttgart . New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20178092     DOI: 10.1055/s-0029-1237396

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  2 in total

1.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.

Authors:  Marie Tournier; Bernard Bégaud; Audrey Cougnard; Guy-Robert Auleley; Jean Deligne; Claudine Blum-Boisgard; Anne C M Thiébaut; Hélène Verdoux
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  Commentary on a recent review of lithium toxicity: what are its implications for clinical practice?

Authors:  Bruno Müller-Oerlinghausen; Michael Bauer; Paul Grof
Journal:  BMC Med       Date:  2012-11-02       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.